HC Wainwright Boosts Earnings Estimates for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP) – Investment analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of Spyglass Pharma in a research note issued to investors on Friday, May 29th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their previous forecast of ($0.47). HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.08) EPS and FY2027 earnings at ($2.14) EPS.

Several other analysts have also issued reports on the stock. Zacks Research raised shares of Spyglass Pharma to a “hold” rating in a research report on Wednesday, March 4th. Stifel Nicolaus started coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price objective for the company. Citigroup started coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price objective for the company. Jefferies Financial Group started coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $62.00 price objective for the company. Finally, Wall Street Zen cut shares of Spyglass Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

Spyglass Pharma Stock Performance

NASDAQ SGP opened at $18.32 on Tuesday. The company has a 50 day simple moving average of $23.12. Spyglass Pharma has a 12-month low of $18.18 and a 12-month high of $32.44.

Spyglass Pharma (NASDAQ:SGP) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.02).

Hedge Funds Weigh In On Spyglass Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of SGP. The Manufacturers Life Insurance Company bought a new stake in Spyglass Pharma during the 1st quarter valued at $308,000. Bank of America Corp DE bought a new stake in Spyglass Pharma during the 1st quarter valued at $726,000. Monashee Investment Management LLC bought a new stake in Spyglass Pharma during the 1st quarter valued at $2,461,000. Affinity Asset Advisors LLC bought a new stake in Spyglass Pharma during the 1st quarter valued at $6,478,000. Finally, First Light Asset Management LLC bought a new stake in Spyglass Pharma during the 1st quarter valued at $9,716,000.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).